Prévisions du marché européen des thérapies contre le cancer du sein jusqu\'en 2030 – Analyse régionale – par thérapie médicamenteuse [thérapie médicamenteuse ciblée (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab et autres thérapies médicamenteuses cibles), thérapie médicamenteuse hormonale (modulateurs sélectifs des récepteurs des œstrogènes, inhibiteurs de l\'aromatase, et régulateurs sélectifs des récepteurs des œstrogènes), chimiothérapie et immunothérapie/thérapie biologique], type de cancer du sein (récepteur hormonal, HER2+ et cancer du sein triple négatif) et canal de distribution (pharmacies hospitalières, pharmacies et pharmacies de détail et pharmacies en ligne) X
Le soutien accru du gouvernement et des organisations privées alimente le marché européen des thérapies contre le cancer du sein
Les gouvernements de divers pays reconnaissent l\'importance de lutter contre le cancer du sein et mettre en œuvre des politiques visant à améliorer l’accès à des traitements efficaces. De nombreux gouvernements et organisations privées ont augmenté le financement de la recherche et du développement dans le domaine thérapeutique du cancer du sein, ce qui a abouti au développement de médicaments et de thérapies innovants. L’Initiative de la Commission européenne sur le cancer du sein (ECIBC) offre des soins de base de qualité, universellement accessibles, à tous les niveaux. La mission de l\'ECIBC est de donner aux femmes et aux professionnels de la santé des conseils impartiaux et impartiaux sur le dépistage et les soins, basés sur les recherches scientifiques les plus récentes. L\'investissement accru dans la recherche a permis aux sociétés pharmaceutiques d\'explorer de nouvelles options de traitement et de développer des thérapies hautement ciblées et efficaces pour les patientes atteintes d\'un cancer du sein.
Plusieurs organismes gouvernementaux à travers le monde prennent également des mesures pour améliorer l\'accès à ces traitements en mettant en œuvre des politiques de remboursement et des initiatives de soins de santé qui couvrent le coût des traitements contre le cancer du sein pour les patientes. Cela signifie qu’un plus grand nombre de patientes peuvent se permettre ces traitements et avoir accès aux dernières avancées thérapeutiques contre le cancer du sein. Le soutien accru du gouvernement a également créé un environnement de marché favorable pour les prestataires de soins de santé. Avec plus de financement et de ressources disponibles, les prestataires de soins de santé sont en mesure d\'offrir à leurs patients un plus large éventail d\'options de traitement. Cela améliore les résultats pour les patients et permet aux prestataires de soins de rester compétitifs sur le marché. Dans l’ensemble, le soutien accru des gouvernements et des organisations privées aux traitements contre le cancer du sein a stimulé l’innovation, conduisant à des traitements nouveaux et améliorés. Il a également amélioré l’accès à ces traitements, bénéficiant ainsi à un plus grand nombre de patients. Cela représente une opportunité importante pour la croissance du marché européen des produits thérapeutiques contre le cancer du sein, alors que les sociétés pharmaceutiques et les prestataires de soins de santé continuent d’investir dans des activités de recherche et développement et d’élargir leurs offres pour répondre à la demande croissante.
Aperçu du marché européen des produits thérapeutiques contre le cancer du sein
Le marché européen des produits thérapeutiques contre le cancer du sein est segmenté en Allemagne, au Royaume-Uni, en France, en Italie, en Espagne et dans le reste de l\'Europe. Le cancer du sein est un type de cancer courant au Royaume-Uni. Selon le National Health Service (NHS), environ une femme sur sept reçoit un diagnostic de cancer du sein au cours de sa vie, selon les données britanniques. Chaque année, environ 55 000 femmes reçoivent un diagnostic de cancer du sein.
La demande accrue de l\'industrie médicale pour traiter les patientes atteintes d\'un cancer du sein avec de nouveaux traitements a conduit à des investissements plus importants en R&D, alimentant ainsi la croissance du marché. Breast Cancer Now est le plus grand bailleur de fonds dédié à la recherche sur le cancer du sein au Royaume-Uni. À ce jour, il a investi 308,01 millions de dollars (
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Breast Cancer Therapeutics Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market - Europe Market Analysis
5.1 Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy
6.1 Overview
6.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type
7.1 Overview
7.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Breast Cancer Therapeutics Market - Country Analysis
9.1 Europe Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Europe Breast Cancer Therapeutics Market, Breakdown, by key Country- Revenue (2022) (US$ Million)
9.1.3 Europe Breast Cancer Therapeutics Market, by Country, 2022 and 2030 (%)
9.1.3.1 UK
9.1.3.1.1 UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 UK: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 UK: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 UK: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 UK: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 UK: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Germany
9.1.3.2.1 Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Germany: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Germany: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Germany: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Germany: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Germany: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 France
9.1.3.3.1 France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 France: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 France: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 France: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 France: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 France: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Italy
9.1.3.4.1 Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Italy: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Italy: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Italy: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Italy: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Italy: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.5 Spain
9.1.3.5.1 Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.2 Spain: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.1 Spain: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.2 Spain: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.3 Spain: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.5.4 Spain: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.6 Rest of Europe
9.1.3.6.1 Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.2 Rest of Europe: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.1 Rest of Europe: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.2 Rest of Europe: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.3 Rest of Europe: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.6.4 Rest of Europe: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. Europe Breast Cancer Therapeutics Market Segmentation
Table 2. Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. UK Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. UK Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. UK Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. UK Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Germany Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Germany Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Germany Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. France Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. France Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. France Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. France Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. France Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Italy Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 20. Italy Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 21. Italy Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 22. Italy Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 23. Italy Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 24. Spain Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 25. Spain Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 26. Spain Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 27. Spain Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 28. Spain Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Europe Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Europe Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Europe Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Europe Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Europe Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 36. Glossary of Terms, Breast Cancer Therapeutics Market
List of Figures
Figure 1. Europe Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. Europe Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. Europe Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Growth Strategies in Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe breast cancer therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Europe breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution